- Active, not recruiting
NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory MM
NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
Primary Objectives:
Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B
Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085 at the RP2D in patients with RRMM
Sponsor
Sanofi
ClinicalTrials.gov Identifier: NCT04000282
Official Title: An Open-label, First-in-human, Single Agent, Dose-escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442085 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
First Posted : June 27, 2019
Click here for details on ClinicalTrials.gov
Anti-CD38 Monoclonal Antibody SAR442085 (Code C166376)
Anti-CD38 Monoclonal Antibody SAR442085
SAR 442085
SAR-442085
SAR442085
Drug: SAR442085
Location
United States, California
United States, Massachusetts
United States, Minnesota
United States, North Carolina
United States, Wisconsin
Czechia
France
Greece
Spain
Taiwan